Literature DB >> 10980880

Cardiomyopathy and embolization: risks and benefits of anticoagulation in sinus rhythm.

R Rho1, D DeNofrio, E Loh.   

Abstract

Systemic embolic complications in patients with cardiomyopathy are associated with significant morbidity and mortality. Despite the lack of prospective, randomized control data, the literature supports the use of left ventricular ejection fraction as an important determinant of the need for systemic anticoagulation therapy in patients with systolic dysfunction. This review discusses the risks and benefits of systemic anticoagulation for patients with cardiomyopathy and proposes a treatment algorithm for its initiation.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10980880     DOI： 10.1007/s11886-000-0006-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  25 in total

1.  Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials.

Authors:  P A Heidenreich; T T Lee; B M Massie
Journal:  J Am Coll Cardiol       Date:  1997-07       Impact factor: 24.094

2.  The effect of warfarin on mortality and reinfarction after myocardial infarction.

Authors:  P Smith; H Arnesen; I Holme
Journal:  N Engl J Med       Date:  1990-07-19       Impact factor: 91.245

Review 3.  Hypercoagulability in heart failure.

Authors:  S M Jafri
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

Review 4.  Idiopathic dilated cardiomyopathy.

Authors:  G W Dec; V Fuster
Journal:  N Engl J Med       Date:  1994-12-08       Impact factor: 91.245

5.  Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy.

Authors:  P A Kyrle; C Korninger; H Gössinger; D Glogar; K Lechner; H Niessner; I Pabinger
Journal:  Thromb Haemost       Date:  1985-08-30       Impact factor: 5.249

6.  Ventricular dysfunction and the risk of stroke after myocardial infarction.

Authors:  E Loh; M S Sutton; C C Wun; J L Rouleau; G C Flaker; S S Gottlieb; G A Lamas; L A Moyé; S Z Goldhaber; M A Pfeffer
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

7.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

8.  The coagulation system is activated in idiopathic cardiomyopathy.

Authors:  K Yamamoto; U Ikeda; K Furuhashi; M Irokawa; T Nakayama; K Shimada
Journal:  J Am Coll Cardiol       Date:  1995-06       Impact factor: 24.094

9.  Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group.

Authors: 
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245
View more
  2 in total

Review 1.  A benefit-risk assessment of agents used in the secondary prevention of stroke.

Authors:  Ronald S MacWalter; Colin P Shirley
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually.

Authors:  Xiaogang Zhu; Zhenhua Wang; Markus W Ferrari; Katharina Ferrari-Kuehne; Javed Bulter; Xiuying Xu; Quanzhong Zhou; Yuhui Zhang; Jian Zhang
Journal:  ESC Heart Fail       Date:  2021-09-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.